[Form 4] NewAmsterdam Pharma Company N.V. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Louise Kooij, Chief Accounting Officer, filed a Form 4 reporting insider sales of NewAmsterdam Pharma Co N.V. The filing shows a sale on 09/03/2025 of 18,073 ordinary shares at a weighted average price of $25.09 per share. After the transaction the reporting person beneficially owns 15,000 shares directly. The filing includes a broker-provided weighted average price and notes that the full price range was not available at filing.

The form is a routine Section 16 disclosure signed on 09/05/2025 and does not include other transactions or derivative positions. All details reported are limited to the specific non-derivative sale and the post-transaction ownership reported by the insider.

Positive

• Reporting compliance: The insider filed the Form 4 promptly and disclosed the sale and post-transaction ownership.
• Continued ownership: The reporting person remains a direct holder of 15,000 shares after the sale.

Negative

• Insider sale: The reporting person disposed of 18,073 ordinary shares on 09/03/2025.
• Price detail limited: The filing reports a broker-weighted average price of $25.09 and notes the price range was unavailable.

Insights

Financial Analyst

TL;DR: Routine insider sale disclosed—limited material impact given remaining direct ownership.

The filing documents a straightforward disposition of 18,073 ordinary shares at a broker-weighted average price of $25.09 on 09/03/2025, leaving the reporting person with 15,000 shares held directly. This is a standard Section 16 reporting event that provides liquidity information about an insider but contains no new operational or financial data about the issuer. Absent additional context such as a pattern of sales, transaction size relative to total outstanding shares, or linked corporate events, this disclosure is informational and typically viewed as neutral from a valuation perspective.

Corporate Governance Expert

TL;DR: Compliance-focused filing; timely reporting of an insider sale under required disclosure rules.

The Form 4 indicates compliance with Section 16 reporting requirements: a sale was reported and the form was signed two days later. The disclosure includes the broker-weighted average price with an explanatory note that the price range was unavailable at filing, which is a common filing detail. No derivative positions or additional changes in beneficial ownership are reported. From a governance perspective, the form shows transparency on an individual officer's transactions but does not by itself indicate governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kooij Louise Frederika

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/03/2025		S		18,073	D	$25.09(1)	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price provided by the broker; additional information, including the price range, if any, is unavailable at the time of filing.

	/s/ Louise Kooij	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Louise Kooij disclose on Form 4 for NewAmsterdam Pharma (NAMSW)?

The Form 4 reports a sale of 18,073 ordinary shares on 09/03/2025 at a broker-weighted average price of $25.09, leaving 15,000 shares beneficially owned directly.

When was the Form 4 signed for the NAMSW insider sale?

The Form 4 was signed by the reporting person on 09/05/2025.

What is the reporting person’s role at NewAmsterdam Pharma in this filing?

The filing identifies the reporting person as an Officer with the title Chief Accounting Officer.

Does the Form 4 report any derivative securities or other transactions for NAMSW?

No. The filing only reports a non-derivative sale of ordinary shares and shows no derivative securities transactions.

Is the $25.09 price in the Form 4 an exact transaction price?

The filing states the $25.09 figure is a broker-provided weighted average price and that the full price range was unavailable at filing.